Share Price and Basic Stock Data
Last Updated: November 10, 2025, 10:52 pm
| PEG Ratio | 6.78 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Wockhardt Ltd, a prominent player in the pharmaceuticals industry, reported a share price of ₹1,296 and a market capitalization of ₹21,067 Cr. The company has experienced fluctuating sales over recent quarters, with revenue standing at ₹595 Cr in June 2022 and rising to ₹753 Cr by September 2023. However, the company recorded a decline in sales to ₹678 Cr in March 2023 and ₹644 Cr in June 2023, before rebounding to ₹701 Cr in December 2023. The trailing twelve months (TTM) sales reached ₹3,011 Cr, indicating a recovery trend compared to the ₹2,651 Cr recorded in March 2023. This revenue trajectory reflects Wockhardt’s efforts to stabilize its operations amidst challenging market conditions, although it is still below historical highs, such as ₹4,830 Cr in March 2014. The company’s operational performance is crucial as it navigates a competitive landscape characterized by pricing pressures and regulatory challenges.
Profitability and Efficiency Metrics
Wockhardt’s profitability metrics indicate significant challenges, with a reported net profit of -₹149 Cr, reflecting ongoing operational difficulties. The company has faced consistent net losses over several quarters, with a net loss of ₹237 Cr in March 2023 and -₹136 Cr in June 2023. The operating profit margin (OPM) stood at 10% in September 2023, a notable improvement compared to -3% in June 2022, but it still lags behind industry standards. Return on equity (ROE) was reported at 1.22%, while return on capital employed (ROCE) was 3.75%, both of which are low compared to typical sector benchmarks. Wockhardt’s cash conversion cycle (CCC) averaged 123 days, indicating inefficiencies in managing working capital, although it improved from 186 days in March 2024 to 123 days in March 2025. These profitability metrics highlight the need for strategic adjustments to enhance operational efficiency and restore investor confidence.
Balance Sheet Strength and Financial Ratios
Wockhardt’s balance sheet reflects a mixed financial position, with total borrowings reported at ₹2,021 Cr and reserves amounting to ₹4,272 Cr. The debt-to-equity ratio stood at 0.42, indicating a moderate level of leverage, which is manageable but raises concerns regarding financial stability given the company’s ongoing losses. The interest coverage ratio (ICR) was recorded at 1.79, suggesting that the company can cover its interest expenses, albeit with limited buffer. The price-to-book value (P/BV) ratio was noted at 5.30x, which is relatively high, indicating that the stock may be overvalued compared to its book value. Furthermore, the current ratio of 1.26 suggests adequate short-term liquidity, although the quick ratio of 0.90 raises concerns about immediate financial obligations. Overall, while Wockhardt possesses some financial strength through its reserves, the persistent losses and high valuation ratios pose significant risks.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Wockhardt illustrates a gradual decline in promoter holdings, which stood at 49.09% as of March 2025, down from 63.83% in September 2022. This reduction may reflect a lack of confidence among promoters in the company’s current trajectory. Foreign institutional investors (FIIs) increased their stake to 7.29%, while domestic institutional investors (DIIs) raised theirs to 11%, indicating a cautious but growing interest from institutional investors. The public shareholding constituted 32.60%, with the total number of shareholders reported at 1,46,918. The declining promoter stake could signal potential concerns regarding the company’s future performance, which may impact investor sentiment. However, the increasing DII participation suggests that some investors see potential value, despite the current challenges. The evolving shareholding dynamics will be pivotal in shaping investor confidence moving forward.
Outlook, Risks, and Final Insight
Wockhardt’s outlook remains contingent on its ability to navigate operational challenges and improve profitability. The company faces several risks, including ongoing net losses, a high P/BV ratio, and declining promoter confidence, which could hinder future fundraising efforts and operational investments. However, potential strengths include a solid reserve base and improving sales trends that may provide a foundation for recovery. If Wockhardt can successfully implement cost-control measures and enhance operational efficiency, it could reverse its current trajectory. Conversely, failure to address these issues may lead to further declines in profitability and investor confidence. The pharmaceutical sector’s inherent volatility, combined with regulatory pressures and market competition, poses additional risks. Therefore, Wockhardt must strategically align its operations and financial management to foster a sustainable path toward recovery.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Wockhardt Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 136 Cr. | 108 | 247/84.3 | 31.0 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,937 Cr. | 453 | 479/192 | 102 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.4 Cr. | 45.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 37.3 Cr. | 25.4 | 29.1/17.0 | 38.8 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,998.92 Cr | 1,191.15 | 55.95 | 199.13 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 595 | 679 | 699 | 678 | 644 | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 |
| Expenses | 611 | 636 | 654 | 675 | 628 | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 |
| Operating Profit | -16 | 43 | 45 | 3 | 16 | 72 | 37 | -59 | 91 | 110 | 128 | 64 | 72 |
| OPM % | -3% | 6% | 6% | 0% | 2% | 10% | 5% | -8% | 12% | 14% | 18% | 9% | 10% |
| Other Income | 57 | -138 | -1 | -64 | 0 | 24 | 8 | 10 | 30 | 9 | 8 | 15 | -77 |
| Interest | 73 | 70 | 83 | 76 | 79 | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 |
| Depreciation | 64 | 65 | 66 | 56 | 55 | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 |
| Profit before tax | -96 | -230 | -105 | -193 | -118 | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 |
| Tax % | -22% | -10% | -3% | 23% | 15% | 109% | -1% | -2% | 167% | 78% | 5% | 105% | -1% |
| Net Profit | -75 | -207 | -102 | -237 | -136 | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 |
| EPS in Rs | -4.65 | -13.12 | -6.66 | -14.44 | -9.30 | -5.34 | -5.76 | -11.02 | -0.91 | -1.43 | 0.86 | -1.54 | -5.54 |
Last Updated: August 20, 2025, 1:10 am
Below is a detailed analysis of the quarterly data for Wockhardt Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 738.00 Cr.. The value appears to be declining and may need further review. It has decreased from 743.00 Cr. (Mar 2025) to 738.00 Cr., marking a decrease of 5.00 Cr..
- For Expenses, as of Jun 2025, the value is 666.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 679.00 Cr. (Mar 2025) to 666.00 Cr., marking a decrease of 13.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 72.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 72.00 Cr., marking an increase of 8.00 Cr..
- For OPM %, as of Jun 2025, the value is 10.00%. The value appears strong and on an upward trend. It has increased from 9.00% (Mar 2025) to 10.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is -77.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Mar 2025) to -77.00 Cr., marking a decrease of 92.00 Cr..
- For Interest, as of Jun 2025, the value is 48.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 48.00 Cr..
- For Depreciation, as of Jun 2025, the value is 56.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 53.00 Cr. (Mar 2025) to 56.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -109.00 Cr.. The value appears to be declining and may need further review. It has decreased from -22.00 Cr. (Mar 2025) to -109.00 Cr., marking a decrease of 87.00 Cr..
- For Tax %, as of Jun 2025, the value is -1.00%. The value appears to be improving (decreasing) as expected. It has decreased from 105.00% (Mar 2025) to -1.00%, marking a decrease of 106.00%.
- For Net Profit, as of Jun 2025, the value is -108.00 Cr.. The value appears to be declining and may need further review. It has decreased from -45.00 Cr. (Mar 2025) to -108.00 Cr., marking a decrease of 63.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -5.54. The value appears to be declining and may need further review. It has decreased from -1.54 (Mar 2025) to -5.54, marking a decrease of 4.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:08 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,830 | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,011 |
| Expenses | 3,805 | 3,772 | 3,959 | 4,002 | 3,935 | 3,604 | 2,725 | 2,771 | 2,932 | 2,550 | 2,707 | 2,619 | 2,637 |
| Operating Profit | 1,026 | 709 | 494 | 13 | 2 | -38 | 119 | -63 | 298 | 101 | 91 | 393 | 374 |
| OPM % | 21% | 16% | 11% | 0% | 0% | -1% | 4% | -2% | 9% | 4% | 3% | 13% | 12% |
| Other Income | 88 | 67 | 66 | 114 | -238 | 116 | 133 | 975 | -163 | -172 | 17 | 62 | -45 |
| Interest | 83 | 55 | 129 | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 254 | 229 |
| Depreciation | 140 | 145 | 142 | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 223 | 217 | 219 |
| Profit before tax | 891 | 575 | 289 | -247 | -641 | -351 | -247 | 417 | -411 | -624 | -420 | -16 | -119 |
| Tax % | 5% | 28% | 13% | -9% | 4% | -38% | -82% | -65% | -32% | -0% | 12% | 256% | |
| Net Profit | 843 | 413 | 252 | -226 | -667 | -217 | -43 | 689 | -279 | -621 | -472 | -57 | -149 |
| EPS in Rs | 58.91 | 28.30 | 17.45 | -13.62 | -42.30 | -13.52 | -4.81 | 47.64 | -16.94 | -38.80 | -30.18 | -2.89 | -7.65 |
| Dividend Payout % | 13% | 54% | 0% | -56% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -51.01% | -38.98% | -189.68% | -195.13% | 67.47% | 80.18% | 1702.33% | -140.49% | -122.58% | 23.99% | 87.92% |
| Change in YoY Net Profit Growth (%) | 0.00% | 12.03% | -150.70% | -5.45% | 262.60% | 12.72% | 1622.14% | -1842.82% | 17.91% | 146.57% | 63.93% |
Wockhardt Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 1% |
| 3 Years: | -2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 15% |
| TTM: | 85% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 40% |
| 3 Years: | 79% |
| 1 Year: | 36% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 0% |
| 3 Years: | -7% |
| Last Year: | -1% |
Last Updated: September 5, 2025, 1:56 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 36 | 60 | 91 | 94 | 89 | 130 | 159 | 124 | 104 | 110 | 81 | 80 |
| Inventory Days | 201 | 250 | 249 | 243 | 174 | 183 | 209 | 256 | 222 | 216 | 201 | 234 |
| Days Payable | 113 | 136 | 144 | 117 | 122 | 187 | 272 | 223 | 265 | 285 | 240 | 191 |
| Cash Conversion Cycle | 124 | 175 | 196 | 220 | 141 | 126 | 97 | 157 | 60 | 41 | 41 | 123 |
| Working Capital Days | -7 | 14 | 52 | 36 | -56 | -51 | -171 | -133 | -116 | -186 | -163 | -23 |
| ROCE % | 18% | 10% | 7% | -1% | -1% | -1% | 0% | 12% | 1% | -0% | -1% | 4% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 642 | 0.29 | 0.03 | 642 | 2025-04-22 17:25:15 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | -3.02 | -32.05 | -38.79 | -20.24 | 61.95 |
| Diluted EPS (Rs.) | -3.02 | -32.05 | -38.79 | -20.24 | 61.68 |
| Cash EPS (Rs.) | 9.88 | -16.17 | -25.69 | -2.22 | 84.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 268.70 | 237.79 | 254.31 | 291.81 | 339.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 268.70 | 237.79 | 254.31 | 291.81 | 339.43 |
| Revenue From Operations / Share (Rs.) | 185.93 | 181.69 | 184.10 | 224.31 | 244.48 |
| PBDIT / Share (Rs.) | 28.09 | 7.92 | 15.49 | 22.08 | 6.25 |
| PBIT / Share (Rs.) | 14.69 | -6.56 | -1.94 | 4.93 | -15.96 |
| PBT / Share (Rs.) | -0.98 | -27.27 | -43.33 | -28.54 | 81.42 |
| Net Profit / Share (Rs.) | -3.52 | -30.65 | -43.13 | -19.38 | 62.16 |
| NP After MI And SOA / Share (Rs.) | -2.90 | -30.06 | -38.82 | -16.94 | 61.93 |
| PBDIT Margin (%) | 15.10 | 4.36 | 8.41 | 9.84 | 2.55 |
| PBIT Margin (%) | 7.90 | -3.60 | -1.05 | 2.19 | -6.52 |
| PBT Margin (%) | -0.53 | -15.01 | -23.53 | -12.72 | 33.30 |
| Net Profit Margin (%) | -1.89 | -16.86 | -23.42 | -8.63 | 25.42 |
| NP After MI And SOA Margin (%) | -1.56 | -16.54 | -21.08 | -7.55 | 25.33 |
| Return on Networth / Equity (%) | -1.07 | -13.78 | -16.66 | -6.33 | 20.31 |
| Return on Capital Employeed (%) | 3.90 | -2.07 | -0.65 | 1.40 | -3.79 |
| Return On Assets (%) | -0.57 | -6.05 | -7.27 | -2.96 | 8.82 |
| Long Term Debt / Equity (X) | 0.27 | 0.26 | 0.06 | 0.09 | 0.14 |
| Total Debt / Equity (X) | 0.42 | 0.62 | 0.56 | 0.48 | 0.46 |
| Asset Turnover Ratio (%) | 0.38 | 0.36 | 0.33 | 0.20 | 0.15 |
| Current Ratio (X) | 1.26 | 0.78 | 0.64 | 0.80 | 0.77 |
| Quick Ratio (X) | 0.90 | 0.55 | 0.45 | 0.56 | 0.52 |
| Inventory Turnover Ratio (X) | 4.41 | 0.95 | 0.72 | 0.47 | 0.48 |
| Interest Coverage Ratio (X) | 1.79 | 0.40 | 0.73 | 1.06 | 0.27 |
| Interest Coverage Ratio (Post Tax) (X) | 0.77 | -0.50 | -0.08 | 0.67 | 0.38 |
| Enterprise Value (Cr.) | 25036.75 | 10872.67 | 4287.88 | 5607.72 | 6250.83 |
| EV / Net Operating Revenue (X) | 8.31 | 3.89 | 1.62 | 1.74 | 2.31 |
| EV / EBITDA (X) | 55.03 | 89.12 | 19.23 | 17.63 | 90.28 |
| MarketCap / Net Operating Revenue (X) | 7.66 | 3.21 | 0.83 | 1.18 | 1.69 |
| Price / BV (X) | 5.30 | 2.68 | 0.66 | 0.98 | 1.36 |
| Price / Net Operating Revenue (X) | 7.66 | 3.21 | 0.83 | 1.18 | 1.69 |
| EarningsYield | 0.00 | -0.05 | -0.25 | -0.06 | 0.14 |
After reviewing the key financial ratios for Wockhardt Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 5. It has increased from -32.05 (Mar 24) to -3.02, marking an increase of 29.03.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.02. This value is below the healthy minimum of 5. It has increased from -32.05 (Mar 24) to -3.02, marking an increase of 29.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.88. This value is within the healthy range. It has increased from -16.17 (Mar 24) to 9.88, marking an increase of 26.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 268.70. It has increased from 237.79 (Mar 24) to 268.70, marking an increase of 30.91.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 268.70. It has increased from 237.79 (Mar 24) to 268.70, marking an increase of 30.91.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 185.93. It has increased from 181.69 (Mar 24) to 185.93, marking an increase of 4.24.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.09. This value is within the healthy range. It has increased from 7.92 (Mar 24) to 28.09, marking an increase of 20.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 14.69. This value is within the healthy range. It has increased from -6.56 (Mar 24) to 14.69, marking an increase of 21.25.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.98. This value is below the healthy minimum of 0. It has increased from -27.27 (Mar 24) to -0.98, marking an increase of 26.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -3.52. This value is below the healthy minimum of 2. It has increased from -30.65 (Mar 24) to -3.52, marking an increase of 27.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.90. This value is below the healthy minimum of 2. It has increased from -30.06 (Mar 24) to -2.90, marking an increase of 27.16.
- For PBDIT Margin (%), as of Mar 25, the value is 15.10. This value is within the healthy range. It has increased from 4.36 (Mar 24) to 15.10, marking an increase of 10.74.
- For PBIT Margin (%), as of Mar 25, the value is 7.90. This value is below the healthy minimum of 10. It has increased from -3.60 (Mar 24) to 7.90, marking an increase of 11.50.
- For PBT Margin (%), as of Mar 25, the value is -0.53. This value is below the healthy minimum of 10. It has increased from -15.01 (Mar 24) to -0.53, marking an increase of 14.48.
- For Net Profit Margin (%), as of Mar 25, the value is -1.89. This value is below the healthy minimum of 5. It has increased from -16.86 (Mar 24) to -1.89, marking an increase of 14.97.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.56. This value is below the healthy minimum of 8. It has increased from -16.54 (Mar 24) to -1.56, marking an increase of 14.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.07. This value is below the healthy minimum of 15. It has increased from -13.78 (Mar 24) to -1.07, marking an increase of 12.71.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.90. This value is below the healthy minimum of 10. It has increased from -2.07 (Mar 24) to 3.90, marking an increase of 5.97.
- For Return On Assets (%), as of Mar 25, the value is -0.57. This value is below the healthy minimum of 5. It has increased from -6.05 (Mar 24) to -0.57, marking an increase of 5.48.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has increased from 0.26 (Mar 24) to 0.27, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.42, marking a decrease of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.38. It has increased from 0.36 (Mar 24) to 0.38, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.26. This value is below the healthy minimum of 1.5. It has increased from 0.78 (Mar 24) to 1.26, marking an increase of 0.48.
- For Quick Ratio (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.55 (Mar 24) to 0.90, marking an increase of 0.35.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.41. This value is within the healthy range. It has increased from 0.95 (Mar 24) to 4.41, marking an increase of 3.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.79. This value is below the healthy minimum of 3. It has increased from 0.40 (Mar 24) to 1.79, marking an increase of 1.39.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 3. It has increased from -0.50 (Mar 24) to 0.77, marking an increase of 1.27.
- For Enterprise Value (Cr.), as of Mar 25, the value is 25,036.75. It has increased from 10,872.67 (Mar 24) to 25,036.75, marking an increase of 14,164.08.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.31. This value exceeds the healthy maximum of 3. It has increased from 3.89 (Mar 24) to 8.31, marking an increase of 4.42.
- For EV / EBITDA (X), as of Mar 25, the value is 55.03. This value exceeds the healthy maximum of 15. It has decreased from 89.12 (Mar 24) to 55.03, marking a decrease of 34.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.66. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 24) to 7.66, marking an increase of 4.45.
- For Price / BV (X), as of Mar 25, the value is 5.30. This value exceeds the healthy maximum of 3. It has increased from 2.68 (Mar 24) to 5.30, marking an increase of 2.62.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.66. This value exceeds the healthy maximum of 3. It has increased from 3.21 (Mar 24) to 7.66, marking an increase of 4.45.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.05 (Mar 24) to 0.00, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Wockhardt Ltd:
- Net Profit Margin: -1.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.9% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.07% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.77
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.9
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 403 (Industry average Stock P/E: 46.92)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -1.89%